Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Slides:



Advertisements
Similar presentations
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Advertisements

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C
Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation  Qing Ma, Dan Li, Roza Nurieva, Rebecca.
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.
The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation 
IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy 
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
CCR2 is required for CD8-induced graft-versus-host disease
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Graft-versus-Host Disease Causes Broad Suppression of Hematopoietic Primitive Cells and Blocks Megakaryocyte Differentiation in a Murine Model  Yan Lin,
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies 
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice  Chien-Chun Steven Pai,
Donor T Cells Administered Over HLA Class II Barriers Mediate Antitumor Immunity without Broad Off-Target Toxicity in a NOD/Scid Mouse Model of Acute.
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal  Patricia A. Taylor,
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W
An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation  Wannee Asavaroengchai,
Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT  Alwi M. Shatry, Derry C. Roopenian, Robert B.
Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels  Chien-Chun Steven.
The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection 
Enrichment of IL-12–Producing Plasmacytoid Dendritic Cells in Donor Bone Marrow Grafts Enhances Graft-versus-Leukemia Activity in Allogeneic Hematopoietic.
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation  Jeffery J. Auletta,
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice  Denis R. Burger, Yvonne Parker, Kathryn.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning  Gabor Varadi,
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation 
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction  Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.
Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease  Xiao Chen, Rupali Das, Richard Komorowski,
CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.
Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells  Christian Scheffold, Yolanda C. Scheffold,
Volume 4, Issue 2, Pages (February 2009)
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:
Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either.
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution  Maria Gendelman, Maryam Yassai,
Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease  Wonyoung Kim, Juyang.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
Presentation transcript:

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft- versus-Graft Effects  Chandra S. Biswas, Christopher T. Sauter, Cavan P. Bailey, Daniel Rittenberg, Xiaoling Luo, Michelle M. Panis, Tulin Budak-Alpdogan, Dolores Grosso, Neal Flomenberg, Onder Alpdogan  Biology of Blood and Marrow Transplantation  Volume 18, Issue 12, Pages 1808-1818 (December 2012) DOI: 10.1016/j.bbmt.2012.09.012 Copyright © 2012 Terms and Conditions

Figure 1 Haploidentical BM engrafted significantly with no signs of GVHD. Lethally irradiated (13 Gy) B6CBAF1 recipients underwent transplantation with 5 × 106 TCD-BM cells from B6D2F1 mice. Mice were euthanized at 4, 6, and 12 weeks after transplantation, and spleens were harvested. Single-cell suspensions were obtained, and splenocytes were stained with anti-H2Kd, anti-CD3, anti-NK1.1, and anti-B220 antibodies. Cells were analyzed by flow cytometry. Donor cells were determined by positive H2Kd expression on the cell surface. Each harvest contained 5 mice. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 2 Recipients of HI SCT shows better antitumor effect than recipients of parent-F1 SCT. Lethally irradiated (13 Gy) B6D2F1 recipients underwent transplantation with 5 × 106 TCD BM cells and 1 × 105 T cells from either B6 or B6CBAF1 mice. (A) All recipients also received 1 × 104 P815 murine mastocytoma cells on the day of transplantation. Mice were analyzed for survival at 100 days posttransplantation. Each group contained 10 mice. Kaplan-Mayer curves are shown. Log-rank analysis was used for statistical analysis. (B) Lethally irradiated (13 Gy) B6D2F1 recipients underwent transplantation with 5 × 106 TCD-BM cells from either a B6 donor or a B6CBAF1. Single-cell suspensions were prepared from the spleens harvested from the recipients at day 10 posttransplantation. With the 51Cr release assay, the cytotoxicity effect of the splenocytes (effector, E) on P815 murine mastocytoma cells (target, T) was measured at different E/T ratios, as indicated. Each group contained 5 mice. *P < .05. (C and D) B6D2F1 mice underwent transplantation as described in (A). All mice were euthanized on day 28 posttransplantation. Spleens were harvested, and single-cell suspensions were prepared. Splenocytes were stained with anti-H2Kd, anti-CD4, and anti-CD8, followed by intracellular cytokine staining done according to the manufacturer’s protocol (BD Pharmingen, San Diego, CA). The cells were analyzed by multicolor flow cytometry. The total numbers of CD4+ and CD8+ cells are shown in (C). The percentage of donor-derived IFN-γ–and TNF-α–secreting CD8+ T cells are shown in (D). The data are representative of 2 independent experiments. Each group contained 5 mice. The Mann-Whitney U test was used for statistical analysis. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 3 DH-HSCT recipients engrafted well, with no GVHD or graft failure. Lethally irradiated (13 Gy) B6CBAF1 recipients underwent transplantation with 5 × 106 TCD-BM cells from the B6SJLF1 donor (SH1), B6D2F1 donor (SH2), or both donors (DH). (A) Weight curve for the recipients over 90 days posttransplantation. (B-E) Blood was collected via retro orbital bleeding at day 90 from recipients after transplantation and analyzed for WBC (B), neutrophils (NE) (C), hemoglobin (HB) (D), and platelets (PLT) (E). The cells from both HI donors engrafted well in the DH-HSCT recipients. Mice were euthanized at day 90, and spleens and BM cells were harvested. Cells were stained with anti-H2kD, anti-H2kk, anti-H2ks, anti-CD45.1, anti-CD3, anti-B220, Gr-1, and anti-CD11b and analyzed by multicolor flow cytometry. Shown are percent engraftment of total spleen (F and G) and spleen T cells (H), B cells (I), and myeloid cells, and total BM (J) and BM B cells (K), T cells (L), and myeloid cells (M). Each group contained 8 mice, and the experiment was repeated twice. The nonparametric Mann-Whitney U test was used for statistical analysis. *P < .05. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 4 DH-HSCT (B6D2F1 BM + C3D2F1 BM→B6C3F1) engrafted well in recipients of HSCT. Lethally irradiated (13 Gy) B6C3F1 (host) recipients with TCD-BM cells from B6D2F1 (D1) and C3D2F1 (D2) mice, and spleens were harvested on day 35 posttransplantation. (A) In single cell suspensions, cells were stained with anti-H2kd, -H2kk, -H2kb, -CD4, and -CD8 antibodies analyzed by multicolor flow cytometry. (B-D) Chimerism patterns of donor-derived splenocytes (B) and splenic T cells (C), and B cells (D). Each group contained 10 mice. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 5 Single or double donor T cells increased the same type of donor BM engraftment in recipients of DH-HSCT. Lethally irradiated (13 Gy) B6CBAF1 recipients underwent transplantation with 5 × 106 TCD-BM cells from B6SJLF1 (D1), B6D2F1 (D2), or both donor mice (DH). Recipients also received 1 × 105 T cells from either B6SJLF1 (T1) or B6D2F1 (T2) or both donor mice (DT) along with TCD-BM. Mice were euthanized on day 28 posttransplantation. Spleens and BM were harvested, and single cell suspensions were prepared from each organ. These cells were then stained with anti-H2Kd, anti-H2kk, anti-H2Ks, and anti-CD45.1. Cells were analyzed by multicolor flow cytometry. The percent engraftment of total spleen (A) and BM (B) cells are shown. Each group contained 8-10 mice. *P < .05. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 6 Early engraftment pattern in DH-HSCT recipients does not predict the long-term engraftment pattern. Data from repeated DH-HSCT experiments were compiled and compared for the analysis and prediction of donor (D1 and D2)-derived cellular engraftment pattern in the spleens of host at early and late posttransplantation. Shown are chimerism patterns of spleen cells (A) and splenic T cells (B), B cells (C), and NK cells (D) at days 30, 60, and 90 posttransplantation from DH-HSCT experiments. The total number of mice studied on each day varied between 10 and 20. Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions

Figure 7 DH-HSCT does not abrogate antitumor activity. (A) Lethally irradiated (13 Gy) B6D2F1 recipients underwent transplantation with 5 × 106 TCD-BM cells from B6SJLF1, B6CBAF1, or both donor mice. (B) Some mice received 1 × 105 T cells from B6SJLF1, B6CBAF1, or both donor mice. (C) B6D2F1 mice received BM from B6SJLF1 with a titrated T cell dose between 1 × 105 and 1 × 106. All recipients also received 1 × 104 P815 murine mastocytoma cells on the day of transplantation. Survival was assessed for 100 days posttransplantation. Each group contained 10-20 mice. Kaplan-Mayer curves are shown. Log-rank analysis was used for statistical analysis. (D and E) Chimerism patterns of splenocytes and splenic T and B cells were analyzed on day 30 and day 100 posttransplantation, respectively, using similar methods as described in Figure 3. In brief, lethally irradiated (13 Gy) B6D2F1 recipients underwent transplantation with 5 × 106 TCD-BM cells from B6SJLF1 (SH1), B6CBAF1 (SH2), or both donor mice (DH). Biology of Blood and Marrow Transplantation 2012 18, 1808-1818DOI: (10.1016/j.bbmt.2012.09.012) Copyright © 2012 Terms and Conditions